2 activation in growth-promoting signaling pathway induced by several stimuli, including Ang II and PDGF, and suggest the importance of Gax as a common molecule existed in the redox-sensitive growth control pathway.

In conclusion, we demonstrated that Ang II down-regulated Gax expression via redox-sensitive ERK1/2 activation in VSMCs. This implies the possibility that Gax can be one of the inhibitory molecules in Ang II-induced VSMC hypertrophy via redox-sensitive pathway.

Acknowledgments

References

[1] Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci U S A 1991;15, 88(22):10045–8.

[2] de Bono DP, Yang WD. Exposure to low concentrations of hydrogen peroxide causes delayed endothelial cell death and inhibits proliferation of surviving cells. Atherosclerosis 1995;24, 114(2):235–45.

[3] Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 1992;70(3):593–9.

[4] Griendling KK, Ushio-Fukai M. Redox control of vascular smooth muscle proliferation. J Lab Clin Med 1998;132(1):9–15.

[5] Bellas RE, Lee JS, Sonenshein GE. Expression of a constitutive NF-kappa B-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J Clin Invest 1995;96(5):2521–7.

[6] Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995;96(3):1395–404.

[7] Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998;13, 98(15):1487–94.

[8] Pollman MJ, Hall JL, Gibbons GH. Determinants of vascular smooth muscle cell apoptosis after balloon angioplasty injury. Influence of redox state and cell phenotype. Circ Res 1999;8–22, 84(1):113–21.

[9] Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993;91(5):2268–74.

[10] Berk BC, Corson MA. Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res 1997;80(5):607–16.

[11] Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997;95(3):588–93.

[12] Ushio-Fukai M, Alexander RW, Akers M, Griendling KK. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in

vascular smooth muscle cell hypertrophy. J Biol Chem 1998;12,273 (24):15022–9.

[13] Patterson KD, Cleaver O, Gerber WV, Grow MW, Newman CS, Krieg PA. Homeobox genes in cardiovascular development. Curr Top Dev Biol 1998;40:1–44.

[14] Gorski DH, Le Page DF, Patel CV, Copeland NG, Jenkins NA, Walsh K. Molecular cloning of a diverged homeobox gene that is rapidly down-regulated during the G0/G1 transition in vascular smooth muscle cells. Mol Cell Biol 1993;13(6):3722–33.

[15] Smith RC, Branellec D, Gorski DH, Guo K, Perlman H, Dedieu JF, et al. p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. Genes Dev 1997;1, 11(13):1674–89.

[16] Maillard L, Van Belle E, Smith RC, Le Roux A, Denefle P, Steg G, et al. Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty. Cardiovasc Res 1997;35(3):536–46.

[17] Dzau VJ, Gibbons GH. Endothelium and growth factors in vascular remodeling of hypertension. Hypertension 1991;18(Suppl. 5): III115–21.

[18] Itoh H, Pratt RE, Dzau VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 1990; 86(5):1690–7.

[19] Komatsu Y, Itoh H, Suga S, Ogawa Y, Hama N, Kishimoto I, et al. Regulation of endothelial production of C-type natriuretic peptide in coculture with vascular smooth muscle cells. Role of the vascular natriuretic peptide system in vascular growth inhibition. Circ Res 1996;78(4):606–14.

[20] Yamashita J, Itoh H, Ogawa Y, Tamura N, Takaya K, Igaki T, et al. Opposite regulation of Gax homeobox expression by angiotensin II and C-type natriuretic peptide. Hypertension 1997;29(1 Pt. 2): 381–7.

[21] Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, Hirai T, et al. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 1999;274(12):7936–40.

[22] Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, et al. Role of NADH/NADPH oxidase-derived H_2O_2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998;32(3):488–95.

[23] Takahashi E, Berk BC. MAP kinases and vascular smooth muscle function. Acta Physiol Scand 1998;164(4):611–21.

[24] Chakraborti S, Chakraborti T. Oxidant-mediated activation of mitogen-activated protein kinases and nuclear transcription factors in the cardiovascular system: a brief overview. Cell Signal 1998;10 (10):675–83.

[25] Eguchi S, Matsumoto T, Motley ED, Utsunomiya H, Inagami T. Identification of an essential signaling cascade for mitogen-activated protein kinase activation by angiotensin II in cultured vascular smooth muscle cells. J Biol Chem 1996;271(24):14169–75.

[26] Baas AS, Berk BC. Differential activation of mitogen-activated protein kinases by H_2O_2 and O2-in vascular smooth muscle cells. Circ Res 1995;77(1):29–36.

[27] Zafari AM, Ushio-Fukai M, Minieri CA, Akers M, Lassegue B, Griedling KK. Arachidonic acid metabolites mediate angiotensin II-induced NADH/NADPH oxidase activity and hypertrophy in vascular smooth muscle cells. Antioxid Redox Signal 1999;1(2): 167–79.

[28] Abe MK, Kartha S, Karpova AY, Li J, Liu PT, Kuo WL, et al. Hydrogen peroxide activates extracellular signal-regulated kinase via protein kinase C, Raf-1, and MEK1. Am J Respir Cell Mol Biol 1998;18:562–9.

[29] Lee SL, Simon AR, Wang WW, Fanburg BL. H_2O_2 signals 5-HT-induced ERK MAP kinase activation and mitogenesis of smooth muscle cells. Am J Physiol, Lung Cell Mol Physiol 2001;281:L646–52.

[30] Frank GD, Eguchi S, Inagami T, Motley ED. N-acetylcycteine inhibits angiotensin II-mediated activation of extracellular signal-regulated kinase and epidermal growth factor receptor. Biochem Biophys Res Commun 2001;280(4):1116–9.

[31] Huot J, Houle F, Marceau F, Landry J. Oxidative stress-induced actin reorganization mediated by the p38mitogen-activated protein kinase/ heat shock protein 27 pathway in vascular endothelial cells. Circ Res 1997;80(3):383–92.

[32] Tsai JC, Jain M, Hsieh CM, Lee WS, Yoshimizu M, Patterson C, et al. Induction of apoptosos by pyrrolidinedithiocarbamate and N-acetyl-cysteine in vascular smooth muscle cells. J Biol Chem 1996;271(7): 3667–70.

[33] Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H_2O_2 for platelet-derived growth factor signal transduction. Science 1995;270(5234):296–9.

JBC Papers in Press. Published on February 8, 2005 as Manuscript M411358200

TRANSGENIC EXPRESSION OF GHRELIN IN PANCREAS

−57−

Analysis of Rat Insulin II Promoter-Ghrelin Transgenic Mice and Rat Glucagon

Promoter-Ghrelin Transgenic Mice

Hiroshi Iwakura[1], Kiminori Hosoda[1], Choel Son[1], Junji Fujikura[1], Tsutomu Tomita[1],

Michio Noguchi[1], Hiroyuki Ariyasu[1], Kazuhiko Takaya[2,3], Hiroaki Masuzaki[1],

Yoshihiro Ogawa[1], Tatsuya Hayashi[1], Gen Inoue[1], Takashi Akamizu[3], Hiroshi Hosoda[3,5],

Masayasu Kojima[4], Hiroshi Itoh[1], Shinya Toyokuni[2], Kenji Kangawa[3,5], and Kazuwa

Nakao[1]

[1]Department of Medicine and Clinical Science, Endocrinology and Metabolism and

[2]Department of Pathology and Biology of Diseases, Kyoto University Graduate School

of Medicine, Kyoto 606-8507, Japan

[3]Translational research center, Kyoto University Hospital, Kyoto 606-8507, Japan

[4] Molecular Genetics, Institute of Life Science, Kurume University, Fukuoka 839-0861,

Japan

[5]Department of Biochemistry, National Cardiovascular Center Research Institute, Osaka

565-8565, Japan

Address correspondence to: Kiminori Hosoda, M.D., Ph.D., Department of Medicine

and Clinical Science, Endocrinology and Metabolism, Kyoto University Graduate

1

TRANSGENIC EXPRESSION OF GHRELIN IN PANCREAS

School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.

TEL: +81-75-751-3172; FAX: +81-75-771-9452; kh@kuhp.kyoto-u.ac.jp

2

Summary

We developed and analyzed two types of transgenic mice: rat insulin II promoter–ghrelin transgenic (RIP-G Tg) and rat glucagon promoter-ghrelin transgenic mice (RGP-G Tg). The pancreatic tissue ghrelin concentration measured by C-terminal RIA and plasma des-acyl ghrelin concentration of RIP-G Tg were about 1,000 times and 3.4 times higher than those of nontransgenic littermates, respectively. The pancreatic tissue n-octanoylated ghrelin concentration measured by N-terminal RIA and plasma active ghrelin concentration of RIP-G Tg were not distinguishable from those of nontransgenic littermates. RIP-G Tg showed suppression of glucose-stimulated insulin secretion. Arginine-stimulated insulin secretion, pancreatic insulin mRNA and peptide levels, β cell mass, islet architecture, GLUT2 and PDX-1 immunoreactivity in RIP-G Tg pancreas were not significantly different from those of nontransgenic littermates. Islet batch incubation study did not show suppression of insulin secretion of RIP-G Tg in vitro. Insulin tolerance test showed lower tendency of blood glucose levels in RIP-G Tg. Taking lower tendency of triglyceride level of RIP-G Tg into consideration, these results may indicate that the suppression of insulin secretion is likely due to the effect of des-acyl ghrelin on insulin sensitivity. RGP-G Tg, in

3

which the pancreatic tissue ghrelin concentration measured by C-RIA was about 50 times higher than that of nontransgenic littermates, showed no significant changes in insulin secretion, glucose metabolism, islet mass and islet architecture. The present study raises the possibility that des-acyl ghrelin may have influence on glucose metabolism.

4

Introduction

Ghrelin is a 28-amino-acid peptide with unique modification of acylation, which is essential for its biological action (1). Ghrelin was originally identified in rat stomach as an endogenous ligand for an orphan receptor, which has been so far called growth hormone secretagogue receptor (GHS-R) (1). Ghrelin expression is detected in the stomach, intestine, hypothalamus, pituitary gland, kidney, placenta and testis (2-6). Ghrelin is involved in a wide variety of the functions including the regulation of growth hormone (GH) release, food intake, gastric acid secretion, gastric motility, blood pressure and cardiac output (7-19).

Recently Date et al. reported that ghrelin is present in α cells of normal human and rat pancreatic islets (20). Volante et al. described ghrelin-expression in β cells of human islet (21). Wierup et al. and Prado et al. reported that ghrelin expressing cell is a new islet cell type distinct from α, β, δ and PP cells in human, rat and mouse islets (22-24). Although there was no apparent change of plasma insulin levels in ghrelin null mouse (25,26), which may indicate that ghrelin is not a direct regulator of insulin secretion in the physiological condition, there have been several reports of the effect of pharmacological dose of ghrelin on insulin secretion. Broglio et al., Egido et al. and Reimer et al. have reported that ghrelin has inhibitory effect on insulin secretion (27-30).

5

Adeghate et al., Date et al. and Lee et al. have reported that ghrelin stimulates insulin secretion (20,31,32). Salehi et al. has reported ghrelin has both inhibitory and stimulatory effects depending on its concentration (33). Therefore, there is still a lot of controversy about the localization of ghrelin in the pancreas and the effects of ghrelin on the insulin secretion. As for the effects of des-acyl ghrelin on insulin secretion, Broglio et al. has reported that acute des-acyl ghrelin administration has no effect on insulin secretion in human (34), but that it counteracts the inhibitory effect of n-octanoylated ghrelin on insulin secretion when co-administrated with n-octanoylated ghrelin (35).

Here we developed and analyzed two types of transgenic mice: rat insulin II promoter-ghrelin transgenic mice (RIP-G Tg) and rat glucagon promoter-ghrelin transgenic mice (RGP-G Tg). The purpose of this study was to clarify the effect of transgenic overexpression of ghrelin cDNA in pancreatic islets.

6

Experimental Procedures

Generating RIP- and RGP-ghrelin transgenic mice. Mouse stomach cDNA library

was constructed from 1 µg of mouse stomach poly (A)$^+$ RNA with cDNA synthesis kit

(Amersham Pharmacia Biotech, Uppsala, Sweden). Mouse ghrelin cDNA was isolated

from this library, using rat ghrelin cDNA as a probe. A fusion gene comprising RIP

and mouse ghrelin cDNA coding sequences was designed. The purified fragment (10

µg/ml) was microinjected into the pronucleus of fertilized C57/B6J mice (SLC,

Shizuoka, Japan) eggs. The viable eggs were transferred into the oviducts of

pseudopregnant female ICR mice (SLC) using standard techniques. Transgenic

founder mice were identified by Southern blot analysis of tail DNAs using the mouse

ghrelin cDNA fragment as a probe. RGP-G Tg was generated similarly. Transgenic

mice were used as heterozygotes. Animals were maintained on standard rat food

(CE-2, 352 kcal/100 g, Japan CLEA, Tokyo, Japan) on a 12 h light/12 h dark cycle.

All experimental procedures were approved by the Kyoto University Graduate School

of Medicine Committee on Animal Research.

Immunohistochemistry. Formalin-fixed, paraffin-embedded tissue sections were

immunostained using the avidin-biotin peroxidase complex method (Vectastain "ABC"

Elite kit, Vector Laboratories, Burlingame, CA) as described previously (36). Serial

7

sections were used and the thickness of each section was 5 μm. Sections were incubated with anti-C-terminal ghrelin [13-28] (1:1000 at final dilution), anti-N-terminal ghrelin [1-11] (1:2000) (1) that recognizes the n-octanoylated portion of ghrelin, anti-glucagon (1:500), anti-insulin (1:500), anti-somatostatin (1:500), anti-pancreatic polypeptide (PP) (1:500) (DAKO, Glostrup, Denmark), anti-PDX-1 (1:2000) (kindly provided by Christopher V. E. Wright)(37) and anti-GLUT2 (1:200) (kindly provided by Bernard Thorens)(38) antisera. Quantification of β cell area was performed in insulin-stained sections by using Axio Vision (Carl Zeiss, Hallbergmoos, Germany) and Scion Image (Scion Corporation, Frederick, MD). Ten sections (200μm interval) for each mouse (n=5) were analyzed. The percentage of β cell area in the pancreas was determined by dividing the area of all insulin-positive cells in one section by the total area of the section.

Measurements of plasma and tissue ghrelin concentrations. Plasma was sampled from 10 weeks old RIP-G Tg and their nontransgenic littermates under ad-lib feeding states considering the promoter activity. From RGP-G Tg and their littermates, it was sampled after overnight fast. Blood was withdrawn from the retroorbital vein or the proximal end of the portal vein under ether anesthesia, immediately transferred to chilled siliconized glass tubes containing Na_2EDTA (1mg/ml) and aprotinin (1000

8

KIU/ml, Ohkura Pharmaceutical, Kyoto, Japan), and centrifuged at 4℃. Hydrogen

chloride was added to the samples at final concentration of 0.1 N immediately after

separation of plasma. Plasma was immediately frozen and stored at −80℃ until assay.

Plasma ghrelin concentration was determined by des-acyl ghrelin ELISA kit and

active-ghrelin ELISA kit that recognizes n-octanoylated-ghrelin (Mitsubishi Kagaku

Iatron, Tokyo, Japan).

As for measurement of tissue ghrelin concentration, pancreata or stomachs were

taken from the 8 weeks old male mice. The rumen was removed from the stomach.

Samples were diced and boiled for 5 minutes in the 10-fold v/w of water. Acetic acid

was added to each solution so that the final concentration was adjusted to 1M, and the

tissues were homogenized. The supernatants were obtained after centrifugation.

Tissue ghrelin concentration was determined by radioimmunoassay (RIA) using

anti-ghrelin [13-28] antiserum (C-RIA) and anti-ghrelin [1-11] antiserum (N-RIA) as

described previously (39).

Measurements of body weight and food consumption. Mice were housed

individually and were allowed free access to standard rat chow. Body weights of mice

were measured weekly. Daily food intake was measured by weighing the pellets

between 9:00 and 10:00 AM.

9

Measurements of % body fat and visceral/subcutaneous fat mass ratio (V/S ratio).

Forty weeks old mice were anesthetized with pentobarbital. Percent body fat and

visceral/subcutaneous fat mass ratio (V/S ratio) of mice were measured by Latheta

LTC-100 (ALOKA, Tokyo, Japan).

Glucose and insulin tolerance tests. For the glucose tolerance test (GTT), after

overnight fast, the mice were injected with 1.5 g/kg glucose intraperitoneally. For the

insulin tolerance test (ITT), after 4 hours fast, mice were injected with 2.0 mU/g human

regular insulin (Novolin R; Novo Nordisk, Bagsvaerd, Denmark) intraperitoneally.

Blood was sampled from the tail vein before and 15, 30, 60, 90, and 120 min after the

injection. Blood glucose levels were determined by glucose oxidase method using

Glutest sensor (Sanwa Kagaku, Kyoto, Japan).

Insulin release. After overnight fast, the mice were injected with 3.0 g/kg glucose or

0.25 g/kg L-arginine intraperitoneally. Plasma was sampled from the tail vein before

and 2, 5, 15, 30, and 60 min after the injection using heparin coated tubes. The

measurement of insulin concentration was carried out by ELISA using ultra sensitive rat

insulin kit (Morinaga, Yokohama, Japan).

Pancreatic insulin concentration. As for measurement of pancreatic insulin

concentration, pancreata were obtained from the mice under the ether anesthesia and

10

homogenized in acid-ethanol. The supernatants were used for assay after centrifugation.

Batch incubation of islet Under the pentobarbital anesthesia, Type IV collagenase (Worthington, Lakewood, NJ) dissolved in Hank's balanced salt solution (HBSS) (1.5 mg/ml) was injected into mouse pancreatic duct. Pancreas was removed and incubated at 37 ℃ for 14 minutes. After washing out collagenase by HBSS, islets were collected by Ficoll gradient and manually picked up so that the sizes of the islets were equal. Islets were incubated at 37 ℃ in RPMI1640 containing 10% FCS for 2 hours and then in Krebs-Ringer bicarbonate buffer (KRBB) containing 3.3 mM glucose and 0.2 % bovine serum albumin (BSA) for 30 minutes. 5 islets were incubated at 37 ℃ in 500 μl of KRBB containing 0.2% BSA and 3.3 or 8.7 or 16.7 mM glucose for 1 hour. After centrifugation, the supernatants were collected. Insulin concentrations in supernatants were determined by rat insulin kit (Morinaga, Yokohama, Japan).

Northern blot analysis and real time quantitative RT-PCR. Total RNA was extracted from pancreata using RNeasy mini kit (QIAGEN K.K., Tokyo, Japan). Filters containing 5 μg of total RNA were prepared. Northern blot analyses were performed as described previously (36) using the mouse insulin II cDNA and human β-actin cDNA (Clontech, Palo Alto, CA) as probes. To confirm that approximately

11

equal amount of total RNA was assayed in Northern blot hybridization analysis, the

density of 18S rRNA in the gel and signal of β-actin in each lane was used. The

hybridization signal intensity was quantitated using an image analyzer BAS-2500 (Fuji

Photo Film, Tokyo, Japan). Reverse transcription (RT) was performed with random

hexamer and SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA). Real time

quantitative PCR was performed with ABI PRISM 7700 Sequence Detection System

(Applied Biosystems, Foster City, CA). The following primers and taqman probe were

used: mouse GHS-R sense, 5 - CACCAACCTCTACCTATCCAGCAT-3 ; antisense,

5 - CTGACAAACTGGAAGAGTTTGCA-3 ; taqman probe,

5 -TCCGATCTGCTCATCTTCCTGTGCATG-3 , mouse ghrelin sense,

5'-GCATGCTCTGGATGGACATG-3'; antisense,

5'-TGGTGGCTTCTTGGATTCCT-3'; taqman probe,

5'-AGCCCAGAGCACCAGAAAGCCCA-3'.

Lipid measurements. Blood was collected from retroorbital vein of 35 weeks old

RIP-G Tg and their nontransgenic littermates. After separation of serum, total

cholesterol, triglyceride, free fatty acid, HDL-cholesterol levels in serum were

determined by Cholesterol E-test Wako, Triglyceride E-test Wako, NEFA C-test Wako

and HDL-cholesterol E-test Wako (Wako Pure Chemical Industries, Osaka, Japan).

12

Statistical analysis.   All values were expressed as means ± SE.   Statistical

significance of difference in mean values was assessed by repeated measures ANOVA

or Student's t-test.

13

Results

Distribution of ghrelin in normal mouse pancreas.   We first examined which cell type of islet cells expresses ghrelin in mouse by immunohistochemistry using anti-C-terminal ghrelin antiserum.   In the most of the islets no ghrelin-like immunoreactivity was detected. C-terminal ghrelin-like immunoreactivity was observed in the periphery of minor proportion of islets of wild type mice (Fig.1A).   Most of the ghrelin positive cells were also glucagon positive by serial section analysis (Fig.1 B) while most of the glucagon positive cells were not ghrelin positive.

Generation of RIP- and RGP-ghrelin transgenic mice.   A fusion gene comprising RIP and mouse ghrelin cDNA coding sequences was designed so that ghrelin expression might be targeted to the pancreatic β cells (Fig. 2A).   The ghrelin mRNA level of RIP-G Tg in pancreas determined by quantitative RT-PCR was about 215 times higher than that of nontransgenic littermates (215.3 ± 40.6 vs. 1.0 ± 0.025 arbitrary unit, n=5, P<0.01).   There was also increment in ghrelin mRNA levels in brain of RIP-G Tg (242.6 ± 17.6 vs. 89.1 ± 27.3 arbitrary unit, n=5, P<0.01).   To confirm the expression of ghrelin transgene in pancreatic β cells, we performed immunohistochemical analysis using anti-C-terminal ghrelin antiserum.   C-terminal ghrelin-like immunoreactivity was observed in the nearly whole area of the islets of the RIP-G Tg (Fig.2C) while it

14

was only seen in the periphery of the islets of their nontransgenic littermates (Fig.1A).

Immunohistochemical analysis using anti-N-terminal ghrelin antiserum showed the

same staining pattern (Fig.2D), indicating that n-octanoylated-ghrelin may be produced

in β cells of this transgenic mouse.   We also stained the brain section of RIP-G Tg.

No ghrelin-like immunoreactivity was detected either with anti-C-terminal or

anti-N-terminal ghrelin antisera (data not shown).   The pancreatic tissue ghrelin

concentration of RIP-G Tg measured by C-RIA was about 1,000 times higher than that

of their nontransgenic littermates (1024 ± 108.9 fmol/mg vs. 1.2 ± 0.1 fmol/mg, n=5,

P<0.01).   This concentration was about one third of the nontransgenic stomach

concentration (3558.1 ± 51.0 fmol/mg, n=5).   The pancreatic tissue ghrelin

concentration of RIP-G Tg measured by N-RIA tended to be also higher than that of

their nontransgenic littermates (0.054 ± 0.017 fmol/mg vs. 0.038 ± 0.006 fmol/mg, n=5,

NS; not significant), but it did not reach statistical significance.   Plasma des-acyl

ghrelin concentration of RIP-G Tg was about 3.4 times higher than that of

nontransgenic littermates under the ad-lib feeding states (2805.5 ± 236.4 vs. $825.9 \pm$

244.4 fmol/ml, n=5, P<0.01, Fig.2G).   We also measured des-acyl ghrelin levels in

portal vein of the mice.   In the nontransgenic mice, the portal des-acyl ghrelin level

was significantly higher than that in retroorbital vein. (1108.0 ± 257.3 fmol/ml vs.

15

825.9±244.4 fmol/ml, n=5, P<0.05, Fig.2G)   The des-acyl ghrelin concentration

collected from portal vein of RIP-G Tg at the same time was much higher than that of

nontransgenic littermates (3671.8±328.6 vs. 1108.0±257.3 fmol/ml, n=5, P<0.01,

Fig.2G).   The step-up of des-acyl ghrelin concentration from retroorbital vein to portal

vein of RIP-G Tg was significantly higher than that of nontransgenic littermates. (866.3

± 182.2 fmol/ml vs. 262.9 ± 59.8 fmol/ml, P<0.01, Fig.2H)   Plasma

n-octanoylated-ghrelin levels in retroorbital and portal vein of RIP-G Tg tended to be

higher than that of their nontransgenic littermates (retroorbital; 78.5±13.4 vs. 66.1±

7.1 fmol/ml, n=5, NS, portal; 104.6±15.3 vs. 71.4±9.0 fmol/ml, n=5, NS), but it did

not reach statistical significance.

We also generated RGP-G Tg, in which ghrelin expression is targeted to the

pancreatic α cells (Fig.2B).   The ghrelin mRNA level Tg in pancreas of RGP-G

determined by quantitative RT-PCR was about 16 times higher than that of

nontransgenic littermates (16.3±1.7 vs. 1.0±0.24 arbitrary unit, n=5, P<0.01).   The

ghrelin mRNA level in duodenum of RGP Tg was not statistically different from that of

nontransgenic littermates (520.1±111.1 vs. 379.1±37.6 arbitrary unit, n=5, NS).   The

ghrelin mRNA level in brain of RGP Tg was not distinguishable from that of

nontransgenic littermates (72.0 ± 6.4 vs. 71.8 ± 7.8 arbitrary unit, n=5, NS).

16

Immunohistochemical analysis showed ghrelin-like immunoreactivity in the periphery of the pancreatic islet of RGP-ghrelin transgenic mouse by both anti-C-terminal ghrelin and anti-N-terminal ghrelin antisera (Fig.2E, F). The pancreatic tissue ghrelin concentrations of RGP-G Tg measured by C-RIA were about 50 times higher than those of their nontransgenic littermates (48.9±2.5 fmol/mg vs. 1.2±0.1 fmol/mg, n=5, P<0.01). The pancreatic tissue ghrelin concentration of RGP-G Tg measured by N-RIA tended to be higher than that of their nontransgenic littermates (0.076±0.019 fmol/mg vs. 0.038±0.006fmol/mg, n=5, NS), but it did not reach statistical significance. The plasma des-acyl ghrelin concentrations in retroorbital vein were not elevated in RGP-G Tg after over night fasting compared to nontransgenic littermates (661.6±38.0 vs. 1024.7±27.1 fmol/ml, n=5). The portal des-acyl ghrelin concentrations of RGP-G Tg were also indistinguishable from those of their nontransgenic littermate (1320.6± 164.7 vs. 1442.9±361.5 fmol/ml, n=5, NS). Plasma n-octanoylated-ghrelin levels in retroorbital and portal vein of RGP-G Tg were indistinguishable from those of their nontransgenic littermates (retroorbital; 98.3±18.7 vs. 133.5±25.3 fmol/ml, n=5, NS, portal; 154.3±20.7 vs. 198.9±34.9 fmol/ml, n=5, NS).

Body weight, food consumption and % body fat. There was no significant difference in body weight and food intake between RIP-G Tg and their nontransgenic

17

littermates (Fig. 3). Percent body fat and V/S ratio of RIP-G Tg were not different from those of nontransgenic littermates (Fig.2C, D). No significant changes were observed in RGP-G Tg, either (data not shown).

Glucose metabolism and insulin secretion. Although no significant differences in blood glucose levels were noted between RIP-G Tg and their nontransgenic littermates on the fasting state and intraperitoneal glucose tolerance tests (IPGTT) (Fig.4A, C), plasma insulin levels 2 and 30 minutes after the glucose injection were significantly decreased in RIP-G Tg compared to those in their nontransgenic littermates (Fig.4D). Suppression of insulin secretion was not observed in RIP-G Tg on intraperitoneal injection of arginine (Fig.4G). Blood glucose level of RIP-G Tg in insulin tolerance test tended to be lower than those of their nontransgenic littermates, but it did not reach statistical significance (Fig. 4H).

No significant differences in blood glucose or insulin levels were observed between RGP-G Tg and their nontransgenic littermates on the fasting state, ad-lib feeding or intraperitoneal (IP) glucose or arginine injection (Fig.4B, E, F and data not shown). Blood glucose levels on insulin tolerance test showed no differences between RGP-ghrelin and their nontransgenic littermates (data not shown).

Islet architecture and β cell mass. We studied the tissue sections of RIP-G Tg to

18